Most Read

Under the multi-year, multi-programme collaboration, the companies will discover, develop, and commercialise therapies for cancer patients. Prelude’s capabilities in medicinal chemistry, targeted protein degradation and clinical development will

The newly expanded, 8,000ft2 space has a test material department. It features advanced equipment and 48 workbenches, with a wide range of services, including flow cytometry, ligand binding

Next year, Basilea will explore multiple hypotheses through preclinical studies to identify the optimal future clinical development programme for tonabacase. Under an exclusive option, Basilea will license tonabacase

The deal will be effected by way of a three-cornered amalgamation between SecureDose, Pharmadrug and its wholly owned subsidiary. As per the terms of this transaction, all the

Designed to serve as an incubator facility, the new modern facility includes ISO 7 cGMP cleanroom suites, as well as research and development (R&D) labs. The ReadyStart cGMP

Donesta is Mithra’s investigational next-generation medicine, which contains Estetrol, to treat menopause symptoms. In July this year, Mithra and Searchlight signed a binding term sheet for a licensing

Under the deal, Moderna will utilise Caris’ library of de-identified, multi-modal data solutions generated from whole exome sequencing, whole transcriptome sequencing, and protein analyses, in addition to claims

FT011 is a first-in-class oral therapy designed to treat chronic fibrosis in multiple organs. It is currently progressing through clinical development for the treatment of scleroderma. It acts

NICE has released the final draft guidance (FDG) that suggests Brukinsa as a recommended treatment for eligible adults with untreated CLL if there is a 17p deletion or